H.R. 3682House117th Congress (2021-2023)In Committee

Improving Transparency to Lower Drug Costs Act of 2021

AI-Generated Summary

Updated February 8, 2026 at 3:54 AM UTC

The Improving Transparency to Lower Drug Costs Act of 2021 would amend the Social Security Act to make information about drug discounts and rebates more publicly available. It requires the Department of Health and Human Services to post data on pharmacy‑benefit managers’ (PBMs) negotiated discounts, fees, and price concessions on its website, helping plan sponsors and the public compare PBM performance. The rule applies to data from the prior calendar year and is aimed at Medicare‑related drug programs.

Key Provisions

Amends Section 1150A to clarify that disclosed information excludes data permitted under a new subsection (e).
Adds a new subsection requiring the HHS Secretary to publish, on the HHS website, data on generic dispensing rates and PBM‑provided information about rebates, discounts, fees, and price concessions for the previous year, starting Jan. 1 2022.
Mandates confidentiality protections: data must be aggregated by drug class (with at least three drugs per class) and displayed so individual drug or plan details cannot be identified.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

3 earlier actions

HouseCommittee Latest Action

Referred to the Subcommittee on Health.

Health Subcommittee

June 2, 2021

View full timeline

HouseIntro Referral

Introduced in House

June 1, 2021

HouseIntro Referral

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Energy and Commerce Committee

June 1, 2021

HouseCommittee

Referred to the Subcommittee on Health.

Health Subcommittee

June 1, 2021

HouseCommittee

Referred to the Subcommittee on Health.

Health Subcommittee

June 2, 2021

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in HouseIssued June 1, 2021

117th CONGRESS

1st Session

H. R. 3682

IN THE HOUSE OF REPRESENTATIVES

June 1, 2021

Ms. Spanberger (for herself and Mr. Arrington) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers.

Short title

This Act may be cited as the Improving Transparency to Lower Drug Costs Act of 2021.

Public disclosure of drug discounts

Section 1150A of the Social Security Act (42 U.S.C. 1320b–23) is amended—

(1)

in subsection (c), in the matter preceding paragraph (1), by inserting (other than as permitted under subsection (e)) after disclosed by the Secretary; and

(2)

by adding at the end the following new subsection:

(e)

Public availability of certain information

(1)

In general

In order to allow the comparison of PBMs’ ability to negotiate rebates, discounts, direct and indirect remuneration fees, administrative fees, and price concessions and the amount of such rebates, discounts, direct and indirect remuneration fees, administrative fees, and price concessions that are passed through to plan sponsors, beginning January 1, 2022, the Secretary shall make available on the Internet website of the Department of Health and Human Services the information with respect to the second preceding calendar year provided to the Secretary on generic dispensing rates (as described in paragraph (1) of subsection (b)) and information provided to the Secretary under paragraphs (2) and (3) of such subsection that, as determined by the Secretary, is with respect to each PBM.

(2)

Availability of data

In carrying out paragraph (1), the Secretary shall ensure the following:

(A)

Confidentiality

The information described in such paragraph is displayed in a manner that prevents the disclosure of information, with respect to an individual drug or an individual plan, on rebates, discounts, direct and indirect remuneration fees, administrative fees, and price concessions.

(B)

Class of drug

The information described in such paragraph is made available by class of drug, using an existing classification system, but only if the class contains such number of drugs, as specified by the Secretary (but not fewer than three drugs), to ensure confidentiality of proprietary information or other information that is prevented to be disclosed under subparagraph (A).